Insulin Glargine + Lixisenatide

Soliqua 100/33

GLP-1 Receptor Agonist GLP-1 SubQ FDA/EMA Label

Half-life

13 hr

Time to Peak

1.5 hr

Steady State

~3 days

Dose Range

15–60 units

Frequency

Daily

Overview

Once-daily injectable combination of basal insulin glargine and GLP-1 receptor agonist lixisenatide for type 2 diabetes. Administered within 1 hour before the first meal of the day.

Mechanism of Action

Fixed-ratio combination of insulin glargine (100 units/mL) and lixisenatide (33 mcg/mL) in a single pen. Provides basal insulin coverage plus GLP-1 post-prandial glucose control.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Subcutaneous (SubQ)	15–60 units	13 hr	1.5 hr	Daily

Storage & Handling

2-8C — Refrigerate before first use. After first use: room temp (up to 30C) for up to 14 days. Do not freeze.

Used in Regimens

Insulin Glargine + Lixisenatide is not currently part of any catalog regimen.

Data Sources

FDA Label Soliqua 100/33 FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Insulin Glargine + Lixisenatide with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.